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Background/Aims: 18F-fluorodeoxyglucose-positron emis-
sion tomography (18F-FDG-PET) reflects biological aggressive-
ness and predicts prognoses in various tumors. Evaluating 
the oncologic significance of the preoperative metabolic phe-
notype might be necessary for planning the surgical strategy 
in resectable pancreatic cancers. Methods: From January 
2010 to December 2015, a total of 93 patients with patho-
logic T3 (pT3) pancreatic cancer were included in this study. 
Clinicopathological parameters and PET parameters were 
evaluated, and transcriptome-wide analysis was performed 
to identify the oncologic impact and molecular landscape of 
the metabolic phenotype of resectable pancreatic cancers. 
Results: Preoperative metabolic tumor volume (MTV)2.5 was 
significantly higher in the pN1 group compared to the pN0 
group (11.1±11.2 vs 6.5±7.8, p=0.031). Higher MTV2.5 val-
ues (MTV2.5 ≥4.5) were associated with multiple lymph node 
metastasis (p=0.003), and the lymph node ratio was also 
significantly higher in resected pT3 pancreatic cancer with 
MTV2.5 ≥4.5 compared to those with MTV2.5 <4.5 (0.12±0.13 
vs 0.05±0.08, p=0.001). Disease-specific survival of pa-
tients with MTV2.5 <4.5 was better than that of patients with 
MTV2.5 ≥4.5 (mean, 28.8 months; 95% confidence interval 
[CI], 40.1 to 57.0 vs mean, 32.6 months; 95% CI, 25.5 to 
39.7; p=0.026). Patients with MTV2.5 ≥4.5 who received 
postoperative adjuvant chemotherapy showed better survival 
outcomes than patients with MTV2.5 ≥4.5 who did not receive 
adjuvant treatment in resected pT3 pancreatic cancers 
(p<0.001). Transcriptome-wide analysis revealed that tumors 
with MTV2.5 ≥4.5 demonstrated significantly different expres-
sion of cancer-related genes reflecting aggressive tumor biol-
ogy. Conclusions: Resectable pancreatic cancer with high 
MTV2.5 is not only associated with lymph node metastasis but 
also early systemic metastasis. The molecular background 
of resectable pancreatic cancer with high MTV2.5 may be as-
sociated with aggressive biologic behavior, which might need 
to be considered when managing resectable pancreatic can-
cers. Further study is mandatory. (Gut Liver 2019;13:356-
365)
Key Words: Pancreatic neoplasms; Positron-emission tomog-
raphy; Metabolic phenotype; Transcriptome-wide analysis
INTRODUCTION
In the early 1920s, Otto Warburg reported that cancer cells 
preferentially metabolize glucose by “aerobic glycolysis,” even 
in the presence of ample oxygen.1 The increased glucose de-
mand has been considered one of the fundamental features of 
cancer and has become the foundation of the clinical applica-
tion of 18F-fluorodeoxyglucose-positron emission tomography 
(18F-FDG-PET) in oncology.2 Cancer cells show an increased up-
take of glucose and FDG.2 Both glucose and FDG are phosphor-
ylated by hexokinase (HK) to prevent their release from cancer 
cells. In contrast to glucose, FDG cannot be further metabolized 
due to the lack of the 2’-OH group, resulting in its accumulation 
in cells proportional to the amount of uptake and HK activity.3 
FDG-PET has emerged as an important clinical tool for cancer 
detection and staging and the monitoring of the response of 
cancer to therapy.4 However, there are some important critiques 
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of the routine use of FDG-PET in clinical oncology. It has been 
observed that FDG-PET is not more effective than conventional 
imaging technology at detecting early pancreatic cancer and 
small metastatic lesions.5 In addition, FDG-PET is not able to 
discriminate the oncologic process of pancreatic cancer from in-
flammatory focal lesions including mass-forming pancreatitis.6 
However, with the clinical experiences of using FDG-PET in 
patients with pancreatic cancer, recent studies have suggested 
that the characteristics of preoperative FDG-PET images are 
strongly associated with aspects of tumor biology,7 such as the 
pathological grade,8 recurrence,9 distant metastasis,10 and long-
term oncologic outcomes.11 Several parameters for FDG-PET are 
being developed to measure the metabolism of cancer lesions 
and to predict aspects of tumor biology and the resultant on-
cologic outcomes. Unlike the maximum standard uptake value 
(SUVmax), which reflects the metabolic activity of a single pixel, 
the metabolic tumor volume (MTV) and total lesion glycolysis 
(TLG) can measure the volume-based metabolic activity of the 
entire tumor lesion.11 In our previous study, the results of the 
propensity score-matched analysis demonstrated that preopera-
tive MTV2.5 greater than 4.5 can predict tumor recurrence and 
long-term survival in patients with resected pancreatic cancer.12 
In addition, it was shown that high FDG uptake in left-sided 
pancreatic cancer is strongly associated with loss of SMAD4, 
subsequently resulting in early systemic metastasis.13 From the 
viewpoint of the American Joint Committee on Cancer (AJCC) 
7th cancer staging system, pathologic T3 (pT3) lesions are the 
most common type of resected pancreatic cancer, regardless of 
the tumor size.14 Therefore, small proportions of T1 and T2 are 
potential confounding factors in the analysis of the oncologic 
impact of PET/computed tomography (CT)-related parameters in 
patients with resected pancreatic cancer. 
In this study, we focused on patients who underwent po-
tentially curative pancreatectomy for pT3 pancreatic cancer 
without neoadjuvant treatment. We determined the value of 
MTV2.5 in predicting the oncologic outcome of resected pancre-
atic cancer, and investigated the differences in gene expression 
in patients with pT3 pancreatic cancer to explain the different 
oncologic outcomes according to the value of MTV2.5. This ap-
proach may be a basis for a patient-oriented surgical approach 
to the treatment of resectable pancreatic cancer in the near fu-
ture. 
MATERIALS AND METHODS 
1. Study period and population
From January 2010 to December 2015, 232 patients under-
went potentially curative pancreatectomy for pancreatic cancers 
in Yonsei University Severance Hospital, Seoul, Korea. Of those 
232 patients, 93 patients with pT3 pancreatic cancer (AJCC 7th) 
without neoadjuvant treatment who had undergone preopera-
tive PET/CT imaging were included in this investigation. This 
study protocol was approved by the Institutional Review Board 
of Severance Hospital with the waiver of informed consent due 
to retrospective study (IRB number: 4-2017-0657). 
2. Clinicopathological parameters
We retrospectively reviewed the medical records of the pa-
tients, and collected information, such as gender, age, tumor 
location, operation type, tumor size, tumor grade (differentia-
tion), pathologic tumor (pT) stage, presence of lymph node me-
tastasis, lymph node ratio (the total number of metastatic lymph 
nodes divided by the total number of retrieved lymph nodes), 
the presence of microscopic perineural invasion, the presence 
of lymphovascular invasion, the recurrence pattern, and the 
time to recurrence, which was defined as the time from surgical 
resection to recurrence or the last clinical follow-up visit at our 
medical center.
3. PET/CT protocol and PET-related parameters
18F-FDG PET/CT scans were performed with the same protocol 
described in our previous study.12 The SUVmax and MTV2.5 were 
measured on PET images using volume viewer software. Each 
tumor was examined with a spherical-shaped volume of interest 
(VOI) that included the entire lesion in the axial, sagittal, and 
coronal planes. By using CT images, the 18F-FDG uptake values 
of normal organs such as the bowel, stomach, and liver were 
not included in the VOI. The SUVmax of the VOI was calculated 
as (decay-corrected activity/tissue volume)/(injected dose/body 
weight). MTV2.5 was defined as the total tumor volume with an 
SUV ≥2.5, and the MTV and mean SUV of the VOI were auto-
matically calculated. The tumor to liver ratio (TLG) was calcu-
lated as (mean SUV) × (MTV). In patients with SUVmax <2.5, the 
MTV2.5 and TLG were not measured. The TLG was calculated as 
the SUVmax/SUVmean of the liver parenchyma to adjust the values 
of different PET scanners.
4. Sample preparation
In total, six tumor samples from each pancreatic cancer pa-
tient were used for the transcriptomics study. Three samples 
were randomly selected from both the MTV high (MTV2.5 ≥4.5) 
group and the MTV low (MTV2.5 <4.5) group. Total RNA was 
extracted from each formalin-fixed paraffin-embedded sample 
using the TRIzol reagent (Molecular Research Center, Inc., Cin-
cinnati, OH, USA) according to the manufacturer’s instructions. 
Following homogenization, 1 mL of solution was transferred 
to a 1.5-mL Eppendorf tube and centrifuged at 12,000 g for 10 
minutes at 4°C to remove any insoluble material. The super-
natant containing the RNA was collected, mixed with 0.2 mL 
of chloroform, and centrifuged at 12,000 g for 15 minutes at 
4°C. After nucleic acids in the aqueous phase were transferred 
to a new tube, the RNA was precipitated by adding 0.5 mL of 
isopropyl alcohol and then recovered by centrifuging the tube 
at 12,000 g for 10 minutes at 4°C. The RNA pellet was washed 
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briefly in 1 mL of 75% ethanol and centrifuged at 7,500 g for 
5 minutes at 4°C. Finally, the total RNA pellet was dissolved 
in nuclease-free water, and its quality and quantity were as-
sessed on an Agilent Bioanalyzer 2100. Gene expression was 
analyzed with the GeneChip® Human Genome U133 Plus 2.0 
Array (Affymetrix, Santa Clara, CA, USA), which is composed 
of over 45,000 probe sets representing approximately 38,500 
well-characterized human genes. For each gene, eleven pairs of 
oligonucleotide probes are synthesized in situ on the arrays.
5. Microarray
Biotinylated cRNA was prepared according to the standard 
Affymetrix protocol from 200 ng of total RNA (Expression 
Analysis Technical Manual, 2001; Affymetrix). Following frag-
mentation, 3 µg of RNA were hybridized for 16 hours at 45°C 
on the GeneChip® Human Genome Array. The GeneChip® was 
washed and stained in the Affymetrix Fluidics Station 450. 
The GeneChip® was scanned using the Affymetrix GeneChip® 
Scanner 3000 7G. The data were analyzed with Robust Mul-
tichip Analysis using the Affymetrix default analysis settings 
and global scaling as the normalization method. The trimmed 
mean target intensity of each array was arbitrarily set to 100. 
The normalized and log transformed intensity values were then 
analyzed using GeneSpring GX 12.6.1 (Agilent Technologies, 
Santa Clara, CA, USA). Fold change filters included the require-
ment that the genes be present in at least 150% of the controls 
for upregulated genes and fewer than 66% of the controls for 
downregulated genes. Through hierarchical clustering, data 
were clustered into groups that behaved similarly across experi-
ments using GeneSpring GX 12.6.1 (Agilent Technologies). The 
clustering algorithm used the Euclidean distance with average 
linkage.
6. Transcriptomics data analysis
The transcriptomics data obtained from the Affymetrix U133 
Plus 2.0 Arrays were used for the calculation of the fold ratio 
and p-value of gene expression levels between MTV2.5 high and 
MTV2.5 low tumor samples. Genes showing significantly dif-
ferential expression between MTV2.5 high and MTV2.5 low tumor 
samples were selected and included in an integrative analysis 
with ingenuity pathway analysis software (Qiagen Inc., Valen-


























































































Fig. 1. Tumor size and MTV2.5 for nodal metastasis. (A) Correlation analysis for tumor size and MTV2.5. (B) Comparison of the difference in tumor 
size and MTV2.5 according to nodal metastasis. (C) The oncologic outcome of lymph node metastasis in resected pT3 pancreatic cancer.
MTV, metabolic tumor volume; pT3, pathologic T3.
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ways, upstream elements, diseases and functions, and regulatory 
effects were performed.
7. Statistics
Continuous variables were described as the means±standard 
deviation, and categorical variables were described as frequen-
cies (%). The Student t-test, chi-squared tests with Fisher exact 
tests, and linear regression analyses were performed. The Pear-
son correlation method was used to calculate the correlation 
coefficients. Survival curves were estimated using the Kaplan-
Meier method to calculate the cumulative recurrence-free sur-
vival rates. Statistical analyses were performed using SPSS 20.0 
for Windows (IBM Corp., Armonk, NY, USA). p-values <0.05 
were considered statistically significant. 
RESULTS
1. Characteristics of patients with resected pT3 pancreatic 
cancer
From January 2010 to December 2015, 232 patients under-
went radical resection for pancreatic cancer. The final study 
population was 93 patients after excluding the patients who 
underwent neoadjuvant treatment or palliative resection. The 
mean age of the study population was 63.6±9.4 years; 53 (57%) 
were males, and 40 (43%) were females.
2. Oncologic outcome of lymph node metastasis in patients 
with resected pT3 pancreatic cancer
Among the clinically available pathologic variables, such as 
the tumor size, degree of differentiation, presence of lympho-
vascular invasion, presence of perineural invasion, presence of 
lymph node metastasis, and resection margin, the Cox propor-
tional hazard model showed that lymph node metastasis was 
the strongest prognostic factor predicting tumor recurrence 
(Exp(β)=1.868, p=0.019). There was a significant difference in 
disease-free survival (DFS) according to the pN stage (mean, 
26.7 months; 95% CI, 18.5 to 34.8 vs mean, 17.7 months; 95% 
CI, 11.4 to 24.0; p=0.017) (Fig. 1C).
3. Preoperative detectable clinical parameter to predict 
lymph node metastasis in patients with resected pT3 
pancreatic cancer
Only the value of preoperative MTV2.5 was significantly 
higher in patients with pN1 than in other patients (6.5±7.8 vs 
11.1±11.2, p=0.031). SUVmax was also marginally significantly 
different between the two groups; however, when adjusted 
by the SUVmean of the liver (tumor to liver ratio), there was no 
significant difference between two groups (1.9±0.8 vs 2.2±1.1, 
p=0.231) (Table 1).
4. Preoperative MTV2.5 ≥4.5 is significantly associated with 
lymph node metastasis in patients with resected pT3 
pancreatic cancer
The previously determined preoperative PET parameter12 of a 




pN0 (n=37) pN1 (n=56)
Age, yr 64.3±9.2 63.2±9.6 0.597
Sex, male/female 23/14 30/26 0.413
Preoperative CA 19-9 575.6±2207.6 886.2±2343.4 0.58
Radiologic tumor size, cm 2.4±0.8 2.8±1.2 0.168
Tumor location, proximal/distal 23/14 38/18 0.572
SUVmax 4.5±2.1 5.5±2.6 0.055
TLR 1.9±0.8 2.2±1.1 0.231
MTV2.5 6.5±7.8 11.1±11.2 0.031
Data are presented as mean±SD or number.
pT3, pathologic T3; SUVmax, maximum standard uptake value; TLR, tumor to liver ratio; MTV, metabolic tumor volume.
Table 2. Preoperative Positron Emission Tomography Parameters to 







   pN0 21 18
   pN1 16 38
Retrieved LNs 19.3±9.4 19.9±10.9 0.76
Metastatic LNs 0.003
   0 21 14
   1 10 15
   ≥2 8 25
LNR 0.05±0.08 0.12±0.13 0.001
Data are presented as number or mean±SD.
pT3, pathologic T3; MTV, metabolic tumor volume; LN, lymph node; 
LNR, lymph node ratio.
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value of MTV2.5≥4.5 was again found to have a close relation-
ship with lymph node metastasis in patients with resected pT3 
pancreatic cancer (p=0.019). In addition, higher MTV2.5 values 
(MTV2.5≥4.5) in patients with pancreatic cancer was found to be 
associated with metastasis to multiple lymph nodes (chi-square, 
linear-to-linear association, p=0.003), and the lymph node ra-
tio was also significantly higher in patients with resected pT3-
pancreatic cancer with MTV2.5 ≥4.5 than in those with MTV2.5 
<4.5 (0.05±0.08 vs 0.12±0.13, p=0.001) (Table 2).
5. Association between MTV2.5 and tumor size according to 
nodal metastasis
To elucidate the confounding effect of tumor size on MTV2.5, 
a correlation analysis and statistical comparisons of tumor 
size and MTV2.5 according to nodal metastasis were performed. 
There was no marked correlation (Pearson correlation coeffi-
cient=0.212) between MTV2.5 and tumor size (Fig. 1A). Though 
the difference in tumor size according to nodal metastasis was 
not statistically significant (p=0.168), the value of MTV2.5 was 
significantly higher in the nodal metastasis group than in the 
group without nodal metastasis (p=0.031) (Fig. 1B).
6. Preoperative MTV2.5 ≥4.5 is significantly associated with 
early systemic metastasis in patients with resected pT3 
pancreatic cancer
Among the 93 patients with resected pT3 pancreatic cancer, 
28 patients (30.1%) experienced early (<6 months after sur-
gery) systemic recurrence. The mean time interval from radi-
cal pancreatectomy to early systemic recurrence was 3.9±2.6 
months. The most frequent distant metastatic site was found 
to be the liver (16/28, 57.1%). pN stage could not predict early 
systemic recurrence in patients with resected pT3 pancreatic 
cancer (p=0.146) (Fig. 2A). A lymph node ratio cutoff value of 
0.07 was shown to determine early systemic recurrence with a 
sensitivity of 60.7% and a specificity of 71.5%. The same cutoff 
value could discriminate those with early systemic metastasis 
from those without with marginal significance in patients with 
resected pT3 pancreatic cancer (p=0.078). However, significantly 
more patients with MTV2.5 ≥4.5 than those with MTV2.5 <4.5 had 
early systemic recurrence after initial radical pancreatectomy 
(p=0.008) (Fig. 2B). Subsequently, the disease-specific survival 
of the patients with MTV2.5 <4.5 was much better than those 
with MTV2.5 ≥4.5 (mean, 28.8 months; 95% CI, 40.1 to 57.0 vs 
mean, 32.6 months; 95% CI, 25.5 to 39.7; p=0.026) (Fig. 3).
7. Postoperative adjuvant chemotherapy attenuates the 
adverse oncologic impact of MTV2.5 ≥4.5 in patients with 
resected pT3 pancreatic cancer
Approximately 80% of patients who underwent curative 
resection received adjuvant treatment based on gemcitabine 
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Fig. 2. Preoperative MTV2.5 parameter and early systemic metastasis in resected pT3 pancreatic cancer. (A) Early systemic recurrence-free survival 
according to nodal metastasis. (B) Early systemic recurrence-free survival according to MTV2.5 value.
































Fig. 3. Disease-specific survival according to the preoperative MTV2.5 
parameter in resected pT3 pancreatic cancer.
MTV, metabolic tumor volume; pT3, pathologic T3.
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tients who received adjuvant treatment after surgery underwent 
chemotherapy with radiation therapy. There was no significant 
difference in the proportion of patients receiving adjuvant treat-
ment according to the level of MTV2.5 (Table 3). Postoperative 
adjuvant chemotherapy could modify the oncologic outcome of 
patients with resected pT3 pancreatic cancer. There was no sig-
nificant difference in the oncologic outcomes (log-rank p=0.352 
in DFS, p=0.142 in overall survival) between patients who re-
ceived adjuvant treatment and those who did not in the MTV2.5 
low group (MTV2.5 <4.5). However, among patients with MTV2.5 
≥4.5, those who received postoperative adjuvant chemotherapy 
had longer DFS times than those who did not receive postopera-
tive adjuvant chemotherapy (mean, 5.7 month; 95% CI, 2.2 to 
9.2 vs mean, 17.4 month; 95% CI, 11.3 to 23.6; p=0.026) (Fig. 
4A); furthermore, the DFS of the former group approached that 
of patients with MTV2.5 <4.5 (mean, 28.3 months; 95% CI, 18.9 
to 37.6; p=0.075). Moreover, the overall disease-specific sur-
vival of patients with MTV2.5 ≥4.5 who underwent postoperative 
chemotherapy became similar to those with MTV2.5 <4.5 (mean, 
34.7 months; 95% CI, 29.9 to 45.2 vs mean, 48.4 months; 95% 
CI, 39.9 to 56.9; p=0.241) (Fig. 4B). In addition, it was found that 
among the 28 patients who experienced early (<6 months after 
surgery) systemic recurrence, only 17 patients (60.7%) received 
postoperative adjuvant chemotherapy, while most patients (58/65 
patients, 89.2%) without early systemic recurrence received post-
operative adjuvant chemotherapy (p=0.001) (Table 4).
8. Genetic background of resected T3 pancreatic cancer 
with MTV2.5 ≥4.5 is associated with aggressive biologic 
behavior; transcriptome-wide analysis discriminating 
gene expression
In total, 85 genes (upregulated in MTV2.5 high: 14 genes; 
downregulated: 71) were identified in the transcriptome-wide 
analysis for differentially expressed genes according to metabol-
ic phenotype (MTV high; MTV2.5 ≥4.5 vs MTV low; MTV2.5 <4.5) 
(Fig. 5A and B, Supplementary Tables 1 and 2, Supplementary 
Figs 1 and 2). Causative analyses using regulator effectors asso-
ciated with the phenotype of the tumors were performed. Master 
regulators (NFKB1, ABL1, EDN1, ABCG2, ADIPOQ, MYD88, 
FOS, and IL1B) were associated with the phenotype of the tu-
mor in terms of the proliferation and invasion of tumor cells 
via several downstream effectors (AKR1B1, NOTCH1, CDKN1A, 
CDKN1B, CD44, CCND1, VEGFA, NFkB, ERK1/2, BCL2, TGFB1, 
Akt, and PI3K). These molecular pathways were significantly 







Adjuvant treatment 29 (78.4) 45 (80.4) 0.812
   Chemoradiation 4 (13.8) 8 (17.8) 0.788
   Chemotherapy only 25 (86.2) 48 (82.2)
Radiation dose, range, Gy 40.3±15.4 41.2±12.3 0.886
Chemotherapy regimen
   Gemcitabine base 16 (55.2) 24 (53.3) 0.728
   5-Fluorouracil base 13 (44.8) 21 (46.7)
Data are presented as number (%).
MTV, metabolic tumor volume.
Table 4. Early Systemic Recurrence According to Postoperative Adju-
vant Chemotherapy
Adjuvant chemotherapy
Early systemic recurrence 
(<6 mo after surgery) p-value
No Yes
Postoperative adjuvant No  7 11 0.001
   chemotherapy Yes 58 17
Fig. 4. The adverse oncologic impact of MTV2.5 ≥4.5 according to postoperative adjuvant chemotherapy in resected pT3 pancreatic cancer. (A) Dis-
ease-free survival according to MTV2.5 subgroup with or without adjuvant chemotherapy (*p=0.00, 
†p=0.075, ‡p=0.026). (B) Disease-specific overall 
survival according to MTV2.5 subgroup with or without adjuvant chemotherapy (
§p<0.001, Ⅱp=0.241, ¶p<0.001).
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correlated with the aggressive tumor phenotype (Fig. 5C, data 
shown in Supplementary Tables 4 and 6). 
A supervised analysis for cancer-specific genes related to the 
hallmarks of cancer was performed using gene set analysis with 
gene sets for oncogenes, tumor suppressor genes, proliferation, 
apoptosis, extracellular remodeling, angiogenesis, immune es-
cape, epithelial-mesenchyme transition, metastasis, and metabo-
lism obtained from the GeneCards database (Supplementary Figs 
2-6).15,16 The upregulated canonical pathways predicted from the 
gene expression pattern of the MTV high tumors were associat-
ed with aberrant immune response, impaired stromal signaling, 
and alternative metabolic pathways (Fig. 6). MTV high tumors 
were strongly associated with the aggressive tumor phenotype 
in terms of the proliferation and invasion of tumor cells, with 
Fig. 5. Hierarchical clustering & significant genes heat map comparing metabolic tumor volume (MTV) high versus low (14 upregulated genes 
and 71 downregulated genes). (A) Hierarchical clustering of significantly expressed genes (fold change >2 or <0.5 with p<0.05). (B) Relative log-
transformed fold changes of MTV high versus low. (C) Causative analysis of regulatory effectors and associated tumor phenotype. Master regula-
tors (NFKB1, ABL1, EDN1, ABCG2, ADIPOQ, MYD88, FOS, and IL1B) were associated with the tumor phenotype in terms of the proliferation and 
invasion of tumor cells via several downstream effectors (AKR1B1, NOTCH1, CDKN1A, CDKN1B, CD44, CCND1, VEGFA, NFkB, ERK1/2, BCL2, 
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Canonical pathway for MTV high tumor2. 5
B cell development
Hepatic fibrosis/hepatic stellate cell activation















Epithelial adherens junction signaling
Macropinocytosis signaling








Fig. 6. Significantly upregulated 
canonical pathways in MTV2.5 high 
tumor samples (data shown in Sup-
plementary Table 3).
MTV, metabolic tumor volume; 
LXR, liver X receptor; RXR, retinoid 
X receptor; IL, interleukin; HIF, 
hypoxia-inducible factor 1; FXR, 
farnesoid X receptor.
Metabolism of carbohydrate
Invasion of tumor cells
Cell viability
Invasion of tumor cell lines
Binding of DNA
Survival of organism
Metabolism of nucleic acid component or derivative
Metabolism of nucleotide
Cell movement of pancreatic cancer cell lines
Activation of antigen presenting cells
Migration of tumor cells
Quantity of carbohydrate
Genital tumor
Proliferation of tumor cells
Cell spreading
Invasion of tumor
Inflammation of body cavity
Contraction of muscle cells
Glomerulosclerosis
Apoptosis of tumor cell lines
Inflammation of organ
Cell death of tumor cell lines
Apoptosis





Diseases or functions for MTV high tumor2. 5
0.0
Activation z-score
4.0 3.5 3.0 2.01.51.00.5 2.50.51.01.52.02.5
Fig. 7. Diseases or functions associated with gene expression pattern of MTV2.5 high tumor samples (data shown in Supplementary Table 5).
MTV, metabolic tumor volume.
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the predicted correlation with disease and function (Fig. 7). The 
landscape of discriminating gene expression levels of cancer-
specific genes according to metabolic phenotype in resected pT3 
pancreatic cancer visualized by Circos plots17 revealed that MTV 
high tumors had markedly higher expression levels of cancer-
specific genes than MTV low tumors, reflecting the biologically 
aggressive behavior of resectable pancreatic cancer (Fig. 8). 
DISCUSSION
Pancreatic cancer is an intractable carcinoma with a dismal 
prognosis due to early systemic metastasis. Even after margin-
negative resection of primary pancreatic cancer, the majority of 
patients undergo systemic metastasis. Early systemic metastasis 
is a major feature of pancreatic cancer even after margin-neg-
ative resection of a primary cancer lesion. Therefore, the identi-
fication of a high-risk group showing aggressive tumor biology 
even among patients with resectable pancreatic cancer is needed 
to improve their oncologic outcomes after curative resection.
Current evidence shows that metabolic phenotypes that can 
be obtained clinically by PET scans before surgical resection can 
predict the oncologic outcomes of patients with various solid 
tumors.18 There is a high likelihood that a primary tumor with 
high metabolic activity has at least a minimal amount of re-
sidual disease that cannot be detected on preoperative imaging 
studies.19,20 
In the treatment of pancreatic cancer, systemic chemotherapy 
is fundamental for improving oncologic outcomes after resec-
tion.19 In fact, in the present study, 15 of 28 patients (53.6%) 
showing early recurrence were found to have systemic metas-
tasis before adjuvant treatment because of their poor general 
condition and their refusal of treatment (11 out of 15 patients). 
Therefore, considering the potential role of systemic chemo-
therapy in treating pancreatic cancer, even resectable pancreatic 
cancer, neoadjuvant chemotherapy might be reasonable in 
patients with pancreatic cancer with high MTV2.5. Our results 
also showed that high metabolic tumors correlated with higher 
node positive rate, early systemic recurrence within 6 months 
after curative resection, and favorable oncologic outcomes in 
response to systemic chemotherapy. It is thought that this popu-
lation can be a potential candidate population for neoadjuvant 
treatment in resectable pancreatic cancer.
In this study, we performed a transcriptome-wide analysis 
using patients’ tumor tissue to reveal the genetic background of 
the differences in metabolic phenotypes identified on PET scans 
preoperatively. The result demonstrated broad enhancement of 
cancer-related gene expression, especially genes related to can-
cer progression and metastasis in the MTV high group (MTV2.5 
≥4.5) compared to the low group (MTV2.5 <4.5). To the best of 
our knowledge, this is rare translational study using clinical 
samples based on metabolic phenotype measured by preopera-
tive images to reveal differences in the molecular landscape ac-
cording to metabolic phenotype.
This retrospective observational study was performed in a 
single institution with a limited study population. The transcrip-
tome-wide analysis was also conducted in small number based 
on metabolic phenotype. In spite of these limitations, our pilot 
translational study showed the prognostic value of metabolic 
phenotype that can be identified by preoperative PET scan. In 
addition, the potential correlation between gene expression 
related to aggressive tumor behavior and high metabolism pan-
creatic cancer can be utilized to suggest neoadjuvant treatment 
and could be beneficial for patients with “apparently” resectable 
pancreatic cancer with high FDG uptake.


















































































































































Fig. 8. Circos plot for the landscape 
of discriminating gene expression 
related to cancer-specific genes ac-
cording to metabolic phenotype in 
resected pT3 pancreatic cancer.
MTV, metabolic tumor volume; pT3, 
pathologic T3; EMT, epithelial mes-
enchymal transition; ECM, extracel-
lular matrix; TSG, tumor suppressor 
gene. 
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In conclusion, resectable pancreatic cancer with high MTV2.5 
is associated with lymph node metastasis and early systemic 
metastasis. Nonetheless, postoperative adjuvant chemotherapy 
attenuated this adverse oncologic impact of high MTV2.5 in re-
sectable pancreatic cancer. The genetic background of resectable 
pancreatic cancer with high MTV2.5 might be associated with 
aggressive biologic behavior. Taken together, neoadjuvant treat-
ment can be a potential alternative even in resectable pancreatic 
cancer with high MTV2.5. A well-designed prospective clinical 
trial with confirmative mechanism study is needed to confirm 
the choice of therapeutic strategy according to metabolic phe-
notype in pancreatic cancer.
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